Bio-Matrix Scientific Group's Subsidiary Applies For Phase II Grant From NCI For The Development Of Immuno-Therapeutic Cancer Vaccine

Main Category: Cancer / Oncology
Also Included In: Immune System / Vaccines;  Clinical Trials / Drug Trials
Article Date: 09 Oct 2009 - 1:00 PDT

email to a friend   printer friendly   opinions  

Entest BioMedical, Inc. (OTCBB: ENTB) a majority owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN) announced today that it has applied for an Exploratory/Development Phase II grant from the National Cancer Institute (NCI).

David Koos, Chairman and CEO of Bio-Matrix Scientific Group and its majority owned subsidiary, Entest BioMedical, Inc. says, "Our goal with this research is to test a viable and groundbreaking cancer treatment, first in the veterinary oncology market and then, if successful, to move on to human clinical trials."

The Entest application involves perfecting the use of cell lines for sustained release of immunologically relevant cytokines for maximum anti-tumor immune responses in treating cancer. The treatment process will utilize an implantable chamber device as the vaccine delivery system. This process has already been demonstrated effective on treating tumors in both rodent and canine models. The grant application has already been assigned to a Scientific Review Group for scientific merit evaluation.

Principal Investigator Dr. Steven F. Josephs says, "If successful, this approach reduces the need for chemotherapy or radiation treatments since the enhanced immune system is engaged in eliminating cancerous tissue on its own. In doing this, we are allowing the subject to recover without the damage that generally occurs with more traditional cancer treatments." Josephs continues, "This work, if successful, should result in a groundbreaking discovery for cancer therapy."

Once efficacy has been achieved in this study, the Company plans to develop a commercially viable treatment for canines, which could impact approximately 36 million dogs in United States that suffer from cancer, according to the Morris Animal Foundation and the American Veterinary Medical Association.

Additionally, Entest BioMedical, Inc. anticipates this treatment option could have marked effects on the human oncology market, which the National Cancer Institute (NCI) estimated at more than $72 billion in 2004. In 2009, NCI's SEER Cancer Statistics Review estimates that more than 1.4 million men and women in United States will be diagnosed with cancer.

About Bio-Matrix Scientific Group

Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is a biotech research and development company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories.

Source
Entest BioMedical Inc.

• Additional
• References
• Citations